Melanoma — Trials · CancerIndex

Clinical trials

Registered studies

3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 606
Recruiting: 317
Ph III recruiting: 30
Growth YoY: +37.2%
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 37.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (571)

clinicaltrialsPublishedShowing 401–450 of 1,140 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04096638	Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors	completed	Phase 1	61	invoX Pharma LimitedINDUSTRY	1	Oct 31, 2024	clinicaltrials
NCT03809624	Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB)	terminated	Phase 1	160	Inhibrx Biosciences, IncINDUSTRY	1	Oct 23, 2024